Dr Mark FarrowUniversity positionProgramme Manager DepartmentsResearch ThemeInterestsTargeted delivery of therapeutics for hard-to-treat cancers Research Focus
EquipmentNo equipment indicated CollaboratorsNo collaborators listed Associated News ItemsPublications2018Purro SA, Farrow MA, Linehan J, Nazari T, Thomas DX, Chen Z, Mengel D, Saito T, Saido T, Rudge P, Brandner S, Walsh DM, Collinge J. (2018), “Transmission of amyloid-β protein pathology from cadaveric pituitary growth hormone.” Nature 564(7736): 415-419 2017Sarell CJ, Quarterman E, Yip DC, Terry C, Nicoll AJ, Wadsworth JDF, Farrow MA, Walsh DM, Collinge J (2017), “Soluble Aβ aggregates can inhibit prion propagation.” Open Biol 2017 7(11) 2015Risse E, Nicoll AJ, Taylor WA, Wright D, Badoni M, Yang X, Farrow MA, Collinge J (2015), “Identification of a Compound That Disrupts Binding of Amyloid-β to the Prion Protein Using a Novel Fluorescence-based Assay.” J Biol Chem 290(27):17020-8 2013Nicoll AJ, Panico S, Freir DB, Wright D, Terry C, Risse E, Herron CE, O'Malley T, Wadsworth JD, Farrow MA, Walsh DM, Saibil HR, Collinge J (2013), “Amyloid-β nanotubes are associated with prion protein-dependent synaptotoxicity.” Nat Commun. 4:2416 2012Klöhn PC, Farmer M, Linehan JM, O'Malley C, Fernandez de Marco M, Taylor W, Farrow M, Khalili-Shirazi A, Brandner S, Collinge J (2012), “PrP antibodies do not trigger mouse hippocampal neuron apoptosis.” Science 335(6064):52 |